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Amyloid peptide (Aβ) aggregates, derived from initial β-site proteolytic processing of the amyloid precursor protein (APP), ac-
cumulate in the brains of Alzheimer’s disease patients. The plasmin-generating cascade appears to serve a protective role in the
central nervous system since plasmin-mediated proteolysis of APP utilizes the α site, eventually generating nontoxic peptides,
and plasmin also degrades Aβ. The conversion of plasminogen to plasmin by tissue-type plasminogen activator in the brain is
negatively regulated by plasminogen activator inhibitor type-1 (PAI-1) resulting in attenuation of plasmin-dependent substrate
degradation with resultant accumulation of Aβ. PAI-1 and its major physiological inducer TGF-β1, moreover, are increased in
models of Alzheimer’s disease and have been implicated in the etiology and progression of human neurodegenerative disorders.
This review highlights the potential role of PAI-1 and TGF-β1 in this process. Current molecular events associated with TGF-β1-
induced PAI-1 transcription are presented with particular relevance to potential targeting of PAI-1 gene expression as a molecular
approach to the therapy of neurodegenerative diseases associated with increased PAI-1 expression such as Alzheimer’s disease.
Copyright © 2006 Paul J. Higgins. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
INTRODUCTION
In patients with Alzheimer’s disease (AD), plaques compris-
edofaggregatedβ-amyloidpeptides(Aβ)accumulateinspe-
ciﬁc areas of the brain as a consequence of the proteolytic
processing of the single-pass transmembrane amyloid pre-
cursor protein (APP) [1]. These Aβ deposits trigger pro-
longed inﬂammation, neuronal death, and progressive cog-
nitive decline [2]. Aβ peptides are derived from APP by β-
site cleavage by an aspartic protease (BACE) producing a
membrane-bound COOH-terminal C99 fragment followed
by a complex proteolytic event (involving presenilin and
nicastrin) at the C99 transmembrane-localized γ position
[3–5]. An alternative APP processing pathway also exists
in which membrane-proximal (α-site) cleavage by matrix
metalloproteinases (TACE, ADAM 10) replaces β position
utilization producing a membrane-anchored C83 fragment.
Subsequent γ-site processing of the C83 product results in
generation of the nontoxic p3 peptide [3, 6].
The broad-spectrum protease plasmin also degrades Aβ
[7–9] and activation of plasmin decreases Aβ peptide lev-
els [10]. Plasmin-mediated proteolysis of APP, moreover, ap-
pearstoinvolvetheαsite(eitherasadirectorindirecttarget)
resulting in decreased Aβ production, thus suggesting a pro-
tectiverolefortheplasmincascadeinthecentralnervoussys-
tem. Indeed, plasmin levels in the brains of AD patients are
considerably reduced [10] further supporting a causal rela-
tionship between deﬁcient activity of the plasmin-generating
proteolytic system and accumulation of Aβ in the progres-
sion of AD.
PLASMIN-ACTIVATING SYSTEM IN
ALZHEIMER’S DISEASE
Several members of the serine protease inhibitor (SERPIN)
superfamily exhibit neurotrophic, neuroprotective, or neu-
ropathophysiologic activities depending on the speciﬁc cell
type and pathways involved [11]. These include SERPINF1,
SERPINI1 (neuroserpin), SERPINE1 (plasminogen activa-
tor inhibitor type-1; PAI-1), SERPINE2 (nexin-1), and SER-
PINA3 [11]. PAI-1, in particular, has multifunctional roles
in the central nervous system as it both maintains neu-
ronal cellular structure and initiates signaling through the
ERK pathway [12]. PAI-1 directly inﬂuences the plasmin-
dependent pericellular proteolytic cascade by regulating the
conversion of plasminogen to plasmin by urokinase- and
tissue-type plasminogen activators (uPA/tPA) (Figure 1).2 Journal of Biomedicine and Biotechnology
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Figure 1: tPA and uPA convert plasminogen to the active, broad-spectrum, protease plasmin both at the cell surface and in the immediate
pericellular space. Plasmin, in turn, degrades target substrates (eg, APP, Aβ) directly as well as indirectly through downstream activation
of matrix metalloproteinases (MMPs). Inhibition of MMP activity (GM6001, TIMP) has conﬁrmed their participation in plasmin-initiated
proteolysis. Most importantly, this cascade is eﬀectively attenuated by overexpression (or exogenous addition) or PAI-1 which blocks tPA
and uPA catalysis inhibiting, thereby, plasmin generation.
PAI-1 immunoreactivity in the central nervous system of
ADpatientswasassociatedwithsenileplaquesandghosttan-
gle structures [13] consistent with the earlier colocalization
of PA and PAI-1 in plaque structures [14]w h i c ha r es i t e s
of sustained inﬂammation [15]. Recent ﬁndings in Tg2576
and TgCRN8 transgenic mice, engineered to express brain-
targeted Swedish mutant Aβ and the double Swedish/V717F
mutant Aβ, respectively, under control of the hamster prion
promoter and exhibit age-dependent Aβ plaque develop-
ment (at 12 and 3 months, resp) as well as cognitive deﬁ-
ciencies [16], established that tPA activity was signiﬁcantly
d e c r e a s e dc o m p a r e dt oc o n t r o l s[ 17]. This decline correlated
with corresponding increases in PAI-1 expression speciﬁcally
in areas of the brain where tPA activity was reduced (hip-
pocampus, amygdala). Since direct Aβ peptide injection in-
creased PAI-1 expression and whereas Aβ removal from the
hippocampal region required both tPA and plasminogen, it
appears that a functional tPA-plasmin axis is required for Aβ
clearance [17]. While PAI-1 may be neuroprotective in spe-
ciﬁc acute injury settings (eg, tPA-triggered neuronal apop-
tosis) [18], chronically elevated PAI-1 levels likely promote
Aβ accumulation by inhibiting plasmin-dependent degrada-
tion (Figure 1).
CONTROLS ON TGF-β1 TARGET GENES:
THE PAI-1 MODEL
Several reports described elevated TGF-β1l e v e l si nb r a i n
biopsies from patients with Parkinson’s disease, AD, and
stroke [20–22]. This growth factor is likely to inﬂuence the
onset and progression of AD at several levels. Increased
brain expression of TGF-β1c o r r e l a t e sw i t hA β angiopa-
thy, and transgenic mice that overexpress TGF-β1i na s -
trocytes exhibit early onset Aβ deposition [23]. TGF-β1,
moreover, induces astrocyte APP expression through a TGF-
β1-responsive AGAC Smad-binding element in the APP pro-
moter; subsequent Aβ production, moreover, was enhanced
by TGF-β1 signaling [24]. Since the PAI-1 gene is also tran-
scriptionally upregulated by TGF-β1[ 19, 25], the coordi-
nate overexpression of PAI-1 and increased Aβ generation
in response to elevated TGF-β1 in the brains of AD patients
may dispose to disease progression [26]. Collectively, these
ﬁndings raise the possibility that targeting TGF-β1-inducible
genes (eg, PAI-1, APP) may have therapeutic beneﬁt in the
setting of AD.
The regulation of TGF-β1-activated genes (ie, PAI-1) is
largely transcriptional [19, 25, 27, 28] with the PAI-1 gene
subjecttocomplexcombinatorialexpressioncontrolsinvolv-
ing the major transcription eﬀectors p53, Sp1, and mem-
bers of the MYC family [19, 29, 30]. Prominent TGF-β-
response elements in the human PAI-1 promoter include
the hexanucleotide E box motif (5 -CACGTG-3 ; as in the
PE1, PE2, HRE-2 sites) and closely related sequences recog-
nized by the basic helix-loop-helix/leucine zipper (bHLH-
LZ)transcriptionfactorsoftheMYCfamily(eg,MYC,MAX,
TFE3, USF-1, and USF-2) [31–36]. This E box element
likely functions, therefore, as a “platform” for recruitment
of both positive and negative regulators of PAI-1 expression
[37–39]. Recent UV crosslinking and tethered DNA aﬃn-
ity chromatographic analyses identiﬁed the bHLH-LZ pro-
tein upstream stimulatory factor-1 (USF-1) as a major PAI-
1 E box-recognition factor [40]. Speciﬁc E box mutations
that ablate USF-1 binding to a PAI-1 target deoxyoligonu-
cleotide probe (CA → TC) eﬀectively attenuated TGF-β1-
stimulated PAI-1 promoter-driven CAT reporter activity
[36]. The human PAI-1 promoter, however, harbors sev-
eral additional TGF-β-responsive elements, including three
E box-adjoining Smad sequences located just 5  of the PE2
site [32, 33, 35, 41]. Since an engineered two-base-pair mu-
tation CACGTG → CAATTG in a serum-responsive PAI-1
E box attenuated growth state as well as TGF-β1-dependent
transcription [36], this same dinucleotide substitution was
incorporated into a luciferase reporter construct bearing the
immediate 806 base pairs of the human PAI-1 5  upstream
region. Initial truncation approaches did, in fact, conﬁrm
thatamajor(albeitnottheonly)TGF-β1-responsiveelement
resided within the most proximal 606 base pairs of the hu-
man PAI-1 promoter [19]. Speciﬁc disruption of the PE2 re-
gion E box element by site-directed mutagenesis signiﬁcantly
attenuated TGF-β1-mediated PAI-1 transcription (Figure 2)Paul J. Higgins 3
−806
5 
PE1
Eb o x
CACGTG
AT
−682 to −677
Smad-
binding
elements
−595 to −569
PE2
Eb o x
CACGTG
AT
−565 to −560
+72
Luciferase
DNase protected
Figure 2: Topography of the PAI-1p806-Luc reporter construct illustrating the two (PE1 and PE2) E box sequences. Site-directed mutagen-
esis and luciferase assays clearly indicated that an intact E box at the PE2 site is required for maximal TGF-β1-induced PAI-1 transcription
in human epithelial cells [19].
[19]. The consequences of USF binding to the PAI-1 PE2 E
box site may be more complex, however, than simple mo-
tif occupancy. Indeed, certain E box-recognition factors in-
cluding USF-1 and USF-2 eﬀectively induce DNA bending.
Cooperative interactions between Sp1 and/or p53 with USF
proteins, for example, may be dependent on USF-initiated
modiﬁcations toDNAconformationallowingdistallyspaced
factors important in expression control to interact with re-
sulting eﬀects on PAI-1 transcription [42].
SEQUENCE REQUIREMENTS FOR USF OCCUPANCY OF
THE PE2 REGION E BOX MOTIF
Chromatin immunoprecipitation recently conﬁrmed that
the PAI-1 PE2 E box site is an in vivo U S Ft a r g e tm o t i f
[38]. Since an intact consensus PE2 region E box sequence is
necessary for a maximal transcriptional response to growth
factors [19], it was important to identify any additional re-
quirements for PE2 E box-occupancy that might inﬂuence
site residence including the Smad-binding AGAC elements
implicated in TGF-β1-dependent APP expression [24]. PE1
and PE2 probes recognition appeared dependent solely on
an intact 5 -CACGTG-3  motif since nuclear factor bind-
ing to individual PE1 and PE2 target constructs was suc-
cessfully blocked by short double-stranded deoxyoligonu-
cleotides containing a consensus E box ﬂanked by non-PAI-1
sequences whereas a mutant E box (5 -CAATTG-3 )“ b a i t ”
failed to compete [19]. It was important, however, to con-
ﬁrm these results using site-speciﬁc mutants within the con-
text of native PAI-1 promoter sequences (eg, the PE2 re-
gion backbone) in order to assess the potential contribu-
tions of the Smad-binding elements, E box ﬂanking nu-
cleotides (such as the AAT trinucleotide “spacer” between
the PE2 E box and the ﬁrst upstream Smad site), and the
CACGTG motif to nuclear protein binding (Figure 2). A re-
cent study established that the major protein/DNA interac-
tions in the PE2 segment were, in fact, E box-dependent and
did not require accessory sites since mutation of all three
Smad-binding sites (AGAC → CTTG) or removal of the
ATT spacer did not aﬀect USF occupancy of the PE2 region
Eb o x[ 19]. While the CACGTG “core” is a target for oc-
cupancy by at least seven members of the bHLH-LZ tran-
scription factor family (USF-1, USF-2, c-MYC, MAX, TFE3,
TFEB, TFII-I), USF proteins have a preference for C or T at
the −4 position in the presence of MgCl2 [43]. Indeed, the
human PAI-1 gene has a T at the −4 site of the PE2 region E
box as well as a purine at +4 and −5 and a pyrimidine at +5
(A−5T−4C−3A−2C−1G+1T+2G+3G+4C+5), all of which facili-
tate USF binding [43]. Chromatin immunoprecipitation of
thePE2regionEboxsiteinthehumanPAI-1gene,moreover,
indicatedadynamicoccupancybyUSFsubtypes(USF-1ver-
sus USF-2) as a function of growth state [44]. This motif was
clearlyaplatformforUSF-1bindinginquiescentcells.Anex-
change of PE2 E box USF-1 homodimers with USF-2 homo-
or USF-1/USF-2 heterodimers, furthermore, closely corre-
lated with PAI-1 gene activation. This switch may well deter-
minethetranscriptionalstatusofthePAI-1geneinquiescent
versus growth factor-stimulated culture conditions [38, 45].
Site occupancy and transcriptional activity additionally re-
quire conservation of the PE2 core E box structure as the
CACGTG → CACGGA and TCCGTG dinucleotide substi-
tutions (in the rat gene) [36]a n daC A C G T G→ CAATTG or
TCCGTG replacement (in the human gene), with retention
of PAI-1 ﬂanking sequences, resulted in loss of both compet-
itive binding and growth factor-dependent reporter activity
[19, 44]. The CACGTG → TCCGTG mutation is particularly
relevantsincebHLHproteinswithEbox-recognitionactivity
have a conserved glutamate important for interaction with
the ﬁrst two nucleotides (CA) in the E box motif [46]. These
data are also consistent with the known hexanucleotide pref-
erence (CACGTG or CACATG) of USF proteins [39, 47, 48].
To further dissect the role of USF in TGFβ1-mediated PAI-
1 transcription in vivo, a dominant-negative USF construct
(A-USF) was implemented for molecular genetic targeting
[19]. A-USF eﬀectively titers away functional USF proteins
by forming highly stable interactions with native USF pro-
teins; such USF/A-USF heterodimers, however, are unable to
bind DNA due to replacement (in the A-USF construct) of
the basic DNA-binding residues with an acidic domain [49].
A-USF transfection eﬀectively attenuated TGF-β1-induced
PAI-1 expression establishing the importance of USF family
transcription factors in PAI-1 gene control [19, 50, 51].
MAPPING THE TGF-β1-INDUCED PAI-1 SIGNALING
AND TRANSCRIPTIONAL CONTROL NETWORKS:
OPPORTUNITIES FOR THERAPEUTIC INTERVENTION
The molecular mechanisms associated with the TGF-β1-in-
itiated E box-dependent PAI-1 gene control and the col-
lateral Smad-mediated APP induction/TGF-β-directed Aβ4 Journal of Biomedicine and Biotechnology
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Figure 3: Pathways involved in the regulation of PAI-1 expression
and function in response to TGF-β1 stimulation. Positve inﬂuences
are depicted in black arrows; eﬀective inhibitors deﬁned pharma-
cologically or by use of dominant-negative constructs (DN) are
highlighted in red (detailed in [50]). CMVIAP = PAI-1 antisense
expression vector.
processing in speciﬁc central nervous system cell types re-
main to be clariﬁed. The available data, however, clearly sug-
gest that these two responses to TGF-β1 are linked in the
pathophysiology of human neurodegenerative disease. It has
become apparent, moreover, that PAI-1 overexpression is a
likely major contributory if not a causative event in AD pro-
gression. Ourcurrent understanding of the pathwaysutilized
by the TGF-β1 to stimulate the PAI-1 transcription (summa-
rized in Figure 3) indicate that this growth factor activates a
kinase cascade, at least partially as a function of epidermal
growth factor receptor mobilization (either through the re-
lease of the appropriate ligands or the direct receptor trans-
activation), involving MEK, ERK1/2, and perhaps p38 [49–
51]. Pharmacological approaches, use of dominant-negative
constructs, and kinase assays suggest that src family kinases
andrasGTPaseareupstreamofMEK-ERK-p38inthismodel
of induced PAI-1 expression [50, 51]. MAP kinases, in turn,
interact with nuclear transcription factors including mem-
bers of the USF family that, once phosphorylated, bind as
d i m e r st oEb o xm o t i f si nt h eP A I - 1p r o m o t e rt om o d u l a t e
gene expression [19, 26, 38, 40, 50, 51]. Genetic perturba-
tion of PAI-1 synthesis in speciﬁc areas of the brain (with
dominant-negative USF or PAI-1 antisense vectors) or deliv-
ery of PAI-1 neutralizing antibodies may eﬀectively stimu-
late uPA- and/or plasmin-dependent target substrate degra-
dation (eg, Aβ) or at least attenuate the rate of Aβ accu-
mulation (Figures 1 and 3). The continued identiﬁcation of
regulatory points in the PAI-1 expression control network
(Figure 3) and recent identiﬁcation of TGF-β1-response sites
(as well as the involved nuclear factors) in the APP and PAI-1
promoters [19, 38, 40, 52] may provide new molecular tar-
gets for the therapy of neurodegenerative syndromes associ-
ated with PAI-1 upregulation. Indeed, speciﬁc SERPINS (in-
cludingPAI-1)havealreadybeensuggestedaspotentialnovel
therapeutic targetsforstrokeand cerebralischemia [12].The
TGF-β1 gene, furthermore, is also USF-regulated [53] sug-
gestingthatinterferencewithUSF-dependenttranscriptional
events may have widespread therapeutic implications.
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